Lakefront Biotherapeutics NV (LKFT) Stock

NASDAQ: LKFTHealthcare company in the biotechnology industry, based in Mechelen, USA.

Lakefront Biotherapeutics stock price chart

LKFT interactive chart →

LKFT stock quote & key statistics

Lakefront Biotherapeutics earnings per share

Income →
Earnings per share

Lakefront Biotherapeutics revenue & net income

Income →
RevenueNet income

Lakefront Biotherapeutics annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$1.11B$320.9M$12.13
FY2024$275.6M$74.1M$0.92
FY2023$239.7M$211.7M—
FY2022$241.2M-$218.0M-$4.27
FY2021$234.4M-$103.2M-$1.63

Fiscal year ending December 31. Source: company filings via EODHD.

About Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Lakefront Biotherapeutics stock FAQ

What is the Lakefront Biotherapeutics stock ticker symbol?

Lakefront Biotherapeutics NV trades on the NASDAQ under the ticker symbol LKFT.

What sector and industry is Lakefront Biotherapeutics in?

Lakefront Biotherapeutics NV is classified in the Healthcare sector, Biotechnology industry.

How many employees does Lakefront Biotherapeutics have?

Lakefront Biotherapeutics NV has about 196 full-time employees.

What were Lakefront Biotherapeutics's revenue and earnings last fiscal year?

Lakefront Biotherapeutics reported revenue of $1.11B and net income of $320.9M in fiscal 2025, with earnings per share of $12.13. Revenue grew 303.5% from the prior year.

When did Lakefront Biotherapeutics go public?

Lakefront Biotherapeutics stock began trading on May 14, 2015.

Biotechnology stocks

All Healthcare stocks →